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Abstract
The International Rare Diseases Research Consortium (IRDiRC) has agreed on IRDiRC Policies and Guidelines, following
extensive deliberations and discussions in 2012 and 2013, as a first step towards improving coordination of research efforts
worldwide. The 25 funding members and 3 patient umbrella organizations (as of early 2013) of IRDiRC, a consortium of
research funders that focuses on improving diagnosis and therapy for rare disease patients, agreed in Dublin, Ireland in April
2013 on the Policies and Guidelines that emphasize collaboration in rare disease research, the involvement of patients and
their representatives in all relevant aspects of research, as well as the sharing of data and resources. The Policies and
Guidelines provide guidance on ontologies, diagnostics, biomarkers, patient registries, biobanks, natural history,
therapeutics, models, publication, intellectual property, and communication. Most IRDiRC members—currently nearly
50 strong—have since incorporated its policies in their funding calls and some have chosen to exceed the requirements laid
out, for instance in relation to data sharing. The IRDiRC Policies and Guidelines are the first, detailed agreement of major
public and private funding organizations worldwide to govern rare disease research, and may serve as a template for other
areas of international research collaboration. While it is too early to assess their full impact on research productivity and
patient benefit, the IRDiRC Policies and Guidelines have already contributed significantly to improving transparency and
collaboration in rare disease research.
Introduction
The International Rare Diseases Research Consortium
(IRDiRC) was launched in 2011 to foster international
research collaboration and investment in the field of rare
diseases, with the aims to contribute to the development of
200 new therapies and the means to diagnose most rare
diseases by the year 2020 [1]. IRDiRC is presently a con-
sortium of nearly 50 funding and patient organizations in 20
countries (Fig. 1) that has the ultimate goal to improve
diagnosis and therapy for patients affected by rare diseases
[2]. Briefly, the composition of members reflected the
implementation of the IRDiRC concept from the high level
discussions between the United States of America National
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Institutes of Health (NIH) and the European Commission
(EC), recognizing the need to bring together research fun-
ders, policy makers, regulators, patient organizations, pre-
mier research institutes, and industry to represent almost
350 million people living with a rare disease. IRDiRC
currently functions through a Consortium Assembly (for-
merly Executive Committee), three Constituent Committees
(Funders, Companies, Patient Advocates), three Scientific
Committees (Diagnostics, Interdisciplinary, Therapies), an
Operating Committee, ad hoc Task Forces, and a Scientific
Secretariat (Fig. 2) [3].
In early 2012, members of the then IRDiRC Executive
Committee, met in Brussels and decided to promote
IRDiRC’s mission through a set of policies and guidelines
that emphasize collaboration in rare disease research. By
early 2013, a draft Policies and Guidelines document,
composed of principles based on recommendations from the
three IRDiRC Scientific Committees on best practices for
rare disease research, was presented to the 25 funding
members and 3 patient umbrella organizations. The IRDiRC
Policies and Guidelines were discussed point-by-point in
April 2013 in Dublin, Ireland, subsequently agreed and
adopted, and made available online on the IRDiRC website
[4]; the rationale is outlined below and the policies and
guidelines are summarized in Table 1. Every member
organization joining IRDiRC is required to commit to
implementing the Policies and Guidelines through their
funding and/or conduct of rare disease research
programmes, while respecting existing national legislation
and organizational requirements.
Rationale of IRDiRC Policies and Guidelines
Generalized principles
The challenge: much rare disease research has been frag-
mented and compartmentalized, leading to lack of integra-
tion, duplication of efforts, lack of critical mass, thinking in
“silos” and inefficient use of resources, therefore hindering
progress towards better diagnosis and therapy for rare dis-
ease patients. Current regulatory and ethical systems can
also be a barrier to collaboration, further increasing the
disadvantage to and vulnerability of rare disease patients.
Most rare diseases are genetic and chronic, leading to long-
term disabilities. They can be difficult to diagnose, most
often lack an effective treatment, and usually require spe-
cialist care and access to expert centers [5]. Additionally,
there are particular difficulties in clinical trials for rare
diseases, which involve small patient numbers and fre-
quently lack well-defined outcomes [6]. However, while
rare diseases are seen as very diverse and different from one
another, commonalities between different rare diseases exist
that can be utilized and exploited, and this is best achieved
through collaborative approaches, e.g., co-development of
model systems common to many rare diseases and sharing
that knowledge and expertise. There is an urgent need for
better integration of rare disease research, in particular with
Fig. 1 IRDiRC members across the different continents. IRDiRC was launched in 2011 with ~30 members and by mid-2017, counts nearly 50
organizations from Asia, Middle East, Australia, Europe, and North America as members
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a view to sharing approaches, resources and data that will
enhance the development of better diagnoses and therapies,
and not reinvent the wheel [7]. This integration mandates a
cultural change while respecting data protection and ethical
approvals, and the direct involvement of all relevant sta-
keholders (scientists, doctors, patients, industry, regulators)
to collectively focus on the key outcome which is improved
health, through better diagnoses and therapies, for people
living with rare diseases worldwide.
Data sharing and standards
To achieve the IRDiRC goals of contributing towards the
development of 200 new therapies and means to diagnose
most rare diseases by 2020, many types of resources and
research data will be generated and shared; this will facil-
itate discovery of genes and treatments while ensuring
efficient resource utilization. Ultimately, it is critical to the
overall success of IRDiRC that datasets obtained from one
project will be directly comparable to datasets obtained
from another, even if generated using a different approach
or technology [8, 9]. This principle has been further
developed into the “International Charter of principles for
sharing bio-specimens and data” [10], which is endorsed by
IRDiRC as one of the “IRDiRC Recognized Resources”
[11]. Other resources and infrastructures for rare diseases
research, including DECIPHER, RD-Connect, and Pheno-
meCentral, have embraced these principles and provide
mechanisms for data sharing. Further “IRDiRC Recognized
Resources” include the HGVS Nomenclature, which sets
forth recommendations to facilitate the report and exchange
of genome information; and the guideline “Framework for
Responsible Sharing of Genomic and Health-Related Data”
[12]. IRDiRC also supports the FAIR Data Principles, that
is, data produced and published by researchers should be
findable, accessible, interoperable, and reusable [13].
Ontologies
Ontologies are a machine readable representation of a
domain of knowledge based upon a controlled, standardized
vocabulary for describing entities and the semantic rela-
tionships between them [14, 15]. Ontologies are increas-
ingly used in different fields in science and medicine as they
are extremely valuable for data integration, organization,
searching, and analysis. Two of the most important kinds of
ontologies for rare disease clinical medicine and research
are ontologies of phenotypic features (signs, symptoms, and
findings of diseases) [15], and ontologies of diseases and
disease groups (nosologies) [16]. It is important that
ontologies are interoperable; this is best achieved if there is
minimal overlap in the concepts covered by the ontologies
(orthogonality) and if the ontologies are semantically
compatible with one another [17, 18]. To date, IRDiRC has
promoted the use of a number of ontology tools, including
Human Phenotype Ontology (HPO) [18], Orphanet Rare
Fig. 2 IRDiRC organigram. IRDiRC functions through a Consortium Assembly, an Operating Committee, three Constituent Committees, three
Scientific Committees, a number of Task Forces, and a Scientific Secretariat
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Table 1 IRDiRC Policies and Guidelines
Type Description
Generalized principles
Policy Rare diseases research should be collaborative. Resources, data and results should be shared among IRDiRC
research projects and made publicly available to the broader community, and duplication should be avoided.
Policy Rare diseases research should involve patients and/or their representatives in all relevant aspects of the research.
Policy International, national, regional and local legislation/regulations need to be adhered to with respect to data
protection and ethical approvals.
Guideline The impact of research on people living with a rare disease should be a key consideration for each project. Best
ethical practices for ensuring the interest of the individuals living with rare diseases should be applied.
Guideline Information about IRDiRC and associated research projects should be disseminated and made available to the
rare diseases communities and the public.
Guideline Education, training and awareness of stakeholders should be encouraged by IRDiRC.
Data sharing and standards
Policy Research projects should adhere to standards endorsed by IRDiRC.
Policy Data producers acknowledge their responsibilities to release data rapidly and to publish initial analyses in a
timely manner. IRDiRC members will encourage and facilitate rapid data release.
Guideline Data generated from research projects, including source data, should be deposited in appropriate open or
controlled access public databases.
Ontologies
Policy IRDiRC members will promote the harmonization, interoperability and open access of ontologies to be applied
to databases, registries, and biobanks.
Guideline Ontologies utilized by rare diseases research projects should build upon existing best practice and allow
integration and interoperability across different ontologies, including those for model organisms. Ontologies
should include rare disease classification ontology (nosology), a phenotype ontology with comprehensive
coverage of rare disease manifestations including laboratory values and imaging, as well as ontologies to support
biobanking, clinical trials, and research.
Diagnostics
Policy IRDiRC members should promote the discovery of all the genes that underlie rare diseases and facilitate the
development of diagnostic testing for most rare diseases.
Policy Research projects should contribute to the development and evolution of standards for rare diseases diagnostic
testing and reporting.
Guideline Research projects should cooperate with efforts to produce a well-curated and interoperable inventory of rare
diseases.
Biomarkers
Policy Research projects should establish criteria and standards for evaluation, qualification and validation of
biomarkers.
Guideline The use of biomarkers in rare diseases therapeutic development should be discussed and agreed with regulatory
authorities through established procedures.
Patient registries
Policy Rare disease patient registries should aim to be global in geographic scope and practice. Interoperability and
harmonization between rare disease patient registries should be consistently pursued. Linking and data transfer
into existing platforms should be considered “best practice”. Registries should be broad and not focused
exclusively around a single therapeutic intervention or product.
Guideline Rare disease patient registries should be linked with data and biological specimens in biobanks, natural history
studies and clinical trials and should include measures of quality control and updating.
Guideline Patients and/or their representatives should be involved in the governance of rare disease registries.
Biobanks
Policy Rare disease biobanks should aim to be global in geographic scope and practice. Interoperability and
harmonization between rare diseases biobanks should be consistently pursued. Linking and data transfer into
existing platforms should be considered “best practice”. Sharing and distributing of biomaterials amongrare
diseases biobanks is highly encouraged.
Guideline Rare diseases biobanks are essential resources and should be sustainable. Rare diseases research studies should
utilize biobanks for processing and storage of biomaterials and should include methods of quality control and
updating.
Guideline Patients and/or their representatives should be involved in the governance of rare diseases biobanks
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Disease Ontology (ORDO) [19], and the set of phenotypic
terms provided by the International Consortium of Human
Phenotype Terminologies [20].
Diagnostics
An accurate molecular diagnosis is essential for informed
patient management and family counseling, as well as for
rare disease research including natural history studies, bio-
marker identification and clinical trials. There are ~7000
rare diseases and the relevant gene is known (as of 2016) for
approximately half of these, thus around 3500 are still
without a defined molecular pathogenesis. In addition, a
significant fraction of rare disease patients are without a
molecular diagnosis due to a lack of universal accessibility
of diagnostic testing. For diagnostic testing to be available
for the majority of rare diseases by the year 2020, IRDiRC
must focus on the discovery of the genes for the 3500
phenotypes that are currently without an associated disease
gene [21]. Another challenge faced is diagnostics beyond
the exome, and approaches to overcome these barriers to




Policy Research projects should contribute to the development and evolution of a set of standards for rare diseases
natural history studies. The outcomes of natural history studies should be considered in the design of clinical
research.
Guideline Patients and/or their representatives should be involved in defining the objectives, the design, the outreach, and
the analysis of clinical research and natural history studies.
Therapeutics
Policy IRDiRC members will encourage the development of therapies that could be approved by 2020, while
respecting each funding entity’s strategic research agenda (including products with an existing orphan
designation, the repurposing of already marketed drugs, or funding preclinical orphan development intended to
substantiate proof-of-concept).
Guideline Clinical investigations supported by IRDiRC funders should meet requirements set by regulatory agencies.
Guideline Adequate scientific and regulatory information about clinical research should be exchanged by researchers.
Guideline IRDiRC members should promote collaborative multinational studies, with common study procedures and
harmonized policies for regulatory and ethical requirements.
Models
Policy IRDiRC members should promote coordination between human and model systems research in RD.
Guideline Prior to proceeding to clinical trials, experimentation providing multiple lines of evidence should be robust,
reproducible and sufficiently powered.
Publication and intellectual property
Policy Research projects should publish their results in a timely manner in peer-reviewed scientific journals, preferably
with open access.
Guideline Research publications should appropriately acknowledge research funding and the use of infrastructures such as
biobanks and registries, as well as the contribution of patients and their representatives.
Guideline IP issues and confidentiality agreements need to be balanced with the need to share information for the benefit of
research and the patient community.
Guideline Rare diseases research should be published even where its outcomes are negative or do not show convincing
results, including clinical trials.
Communication on IRDiRC
Policy IRDiRC members will disseminate relevant information on their research project portfolio through adequate and
timely measures, in particular the IRDiRC website.
Guideline IRDiRC shall publish its mission statement, list of member organizations and list of associated projects. IRDiRC
shall publish non-confidential proceedings, as well as the minutes and approved documents of its Executive
Committee, the Scientific Committees and the Working Groups.
Guideline IRDiRC-associated projects and IRDiRC member organizations should make reference to IRDiRC, where
appropriate, on organizational websites, information material and presentations.
Guideline IRDiRC will promote active exchanges, events and activities between stakeholders, including patient
organizations.
A summary of IRDiRC Policies and Guidelines on generalized principles, data sharing and standards, ontologies, diagnostics, biomarkers, patient
registries, biobanks, natural history, therapeutics, models, publication and intellectual property, and communication on IRDiRC.
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approaches for discovery is required to solve these unsolved
conditions, and IRDiRC aims to gather key researchers and
review strategies to address this challenge [21]. Interna-
tional efforts to establish guidelines for the clinical reporting
of genomic sequencing in a clinical setting, including the
approach to report incidental findings, will expedite the
delivery of high-throughput and cost-effective testing to the
rare diseases patient community as a whole, e.g., guidelines
for diagnostic next-generation sequencing developed by
EuroGentest and the European Society of Human Genetics
[22]. In addition, the necessary bi-directional flow between
the clinic and research will be enabled by the IRDiRC
Policies and Guidelines [23].
Biomarkers
A biomarker is a measurable biological characteristic that is
an indicator of normal biological and pathogenic processes
and/or response to therapeutic or other interventions [24]. It
has been suggested that the use of appropriate biomarkers
can reduce the overall cost of developing new innovative
treatments including therapies for rare diseases. Moreover,
biomarkers may also enhance the efficacy and safety of new
treatments and provide a more rational pathway to facilitate
advances in rare diseases preclinical and clinical therapeutic
development. However, it should be emphasized that the
use of biomarkers in biomedical research has several lim-
itations as they may or may not be correlated with clinical
outcomes. The work needed to understand the relationship
of biomarker changes to either a clinical outcome or other
aspects of a biological system is often substantial and early
dialog with regulatory authorities is essential to facilitate
successful biomarker translation [25].
Patient registries
Patient registries are organized databases where patient
information, including demographic, medical, and family
history, is collected, stored, and available for retrieval via
standardized and secure methods. Patient registries are
increasingly recognized as crucial tools for rare disease
research [26], but there remains a clear need for their
standardization, coordination, and further development.
High-quality and standardized clinical data are critical for
patient registries which requires the systematic use of
ontologies such as the HPO (see above). In particular,
patient registries must overcome the following challenges to
develop their full potential in rare disease research: (a) lack
of harmonization due to high variability among registries
according to rare diseases coding systems, geographical
coverage, and type of data collected; (b) lack of data sharing
since only a minority share data with other databases, bio-
banks or centers of expertise; (c) lack of sustainability since
rare disease patient registries often expire due to lack of
commitment from data providers, lack of funding, or study
termination, leading to loss of data and loss of investment;
and (d) lack of utility for research owing to absence of
quality control, standardized data elements, and genetic
data.
Biobanks
Biobanks are collections of biomaterials with associated
data. Biobanking is an essential tool to provide access to
high-quality human biomaterial and data for fundamental
and translational research. Rare disease research benefits
from the provision of human biomaterials through biobanks,
and each sample from a person with a rare disease has a
high value as it may hold the key to answering an important
research question. The rarity and diversity of rare diseases
and their associated biomaterials present specific challenges
and opportunities for biobanking, requiring transnational
collaboration and harmonization [27, 28]. Providing and
managing information and access to valuable biological
samples through a simple and reliable process is crucial for
rare disease research and will contribute to the development
of new diagnostic techniques, biomarker development,
identification of potential therapeutic targets and testing
therapeutic response. Biobanks need to overcome the fol-
lowing challenges to develop their full potential in rare
disease research: (a) lack of policy for data sharing, access,
attribution and protection, and IT harmonization; (b) lack of
biomaterial and data sharing; (c) lack of sustainability; and
(d) lack of utility for research.
Natural history
Performing natural history studies will facilitate the identi-
fication of disease characteristics that can be used when
planning and conducting clinical investigations for rare
disease therapies. Moreover, this knowledge will also serve
to define a trial’s target population, develop biomarkers for
disease progression and therapeutic response, determine
appropriate surrogate and relevant clinical endpoints, and
decide on the study duration. As rare diseases are highly
diverse in nature, there is no one set of data elements that
can be recommended for data collection in all natural his-
tory rare disease studies; rather the disease characteristics
should reflect the prominent features of the rare disease
[29].
Therapeutics
Clinical trials represent a major challenge for the develop-
ment of therapies intended to treat, cure, or prevent rare
diseases. It is well recognized that clinical investigation in
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this field is associated with several hurdles that may jeo-
pardize the performance of these investigations, when
compared with common diseases. Small patient popula-
tions, together with geographical dispersion, add complex-
ity to the design and performance of trials aimed at
providing efficacy and safety information supporting a
marketing authorization/approval of these therapies [30].
However, introduction of rare diseases legislation and
orphan designation procedures have brought a large number
of investigational products into the development pipeline
[31]. Combined efforts are required of investigators,
industry, patients’ representatives, research institutions, and
regulatory authorities to overcome all bottlenecks asso-
ciated with clinical trials in low-prevalence conditions.
Among the incentives provided by orphan designations,
protocol assistance and scientific advice from regulatory
bodies play a key role in guiding the conduct of studies to
address the benefit/risk analysis for marketing authorization
and approval [32, 33]. Thanks to these strategies, in the US,
47% and 41% of novel drugs approved by the Food and
Drug Administration (FDA) in 2015 and 2016, respectively,
were for rare indications [34, 35]. The trend observed in the
success rates of clinical development between 2006 and
2015 in the US shows higher rates of approval for orphan
products moving on from one phase of clinical studies to
another when compared to drugs for chronic conditions
[36].
Models
Currently, we only understand the biological function of a
fraction of human genes. Animal and cellular models,
including humanized models, provide insight into the
function of genes and the mechanisms underlying rare
diseases can be manipulated experimentally much more
readily than humans for both ethical and technical reasons,
allowing important questions that cannot be addressed in
patients to be approached [37]. Model systems enable
experimental interventions that can establish causal
mechanisms of gene action, thereby putting disease genes
into biological context and can yield pathologic insight that
facilitates the development of targeted therapeutics.
Publication and intellectual property
Rare disease research results should be rapidly shared and
made highly visible to the scientific, health care, patient,
pharmaceutical, and medical device communities. Their
utility must be clearly demonstrated and potential users
must have the opportunity to receive training in the tech-
niques and tools developed. This includes negative results,
which can be as important for the rare disease field as are
new scientific breakthroughs (in relation to data sharing
policies and guidelines). Intellectual Property (IP) is an
important factor for the public and the private sector, in
particular to cover the significant cost of developing new
therapies. Issues related to IP rights need to be assessed and
handled in accordance with fundamental ethical rules and
principles. Tools to handle IP issues may include exploi-
tation and technological implementation plans, non-
exclusive licensing, patenting, knowledge property rights,
and pre-existing know-how. In many instances, con-
fidentiality agreements may be required between the parties
involved.
Communication on IRDiRC
New knowledge, tools, and resources are generated through
the rare disease research funded or supported by IRDiRC
members. Its outputs require high visibility to a range of
stakeholders and a clear strategy to train and educate the
next generation of scientists and other users. The goals of an
external dissemination strategy are to promote international
academic and industrial cross-fertilization, both within and
outside IRDiRC, and to provide information on IRDiRC
research to other research projects, the scientific commu-
nity, industrial groups, government bodies, policy makers,
and the general public, including patients. IRDiRC com-
munication will be built on the principles of openness,
public accessibility, transparency, inclusivity, and time-
liness. Non-confidential discussions and outcomes of
IRDiRC meetings will be reported and published on its
website for access by all stakeholders of rare diseases
research and not only to participating members, and
workshop documents and recommendations will be made
available for public consultations.
Implementation of IRDiRC policies and guidelines
By mid-2017, nearly 50 organizations, including patient
advocacy organizations, from 20 countries have become an
IRDiRC member and accepted IRDiRC Policies and
Guidelines as principles to be implemented in their rare
disease research programmes and contribute to IRDiRC’s
goals. Some of IRDiRC’s principles have been further
developed into more detailed guidance documents, such as
the “International Charter of principles for sharing bio-
specimens and data” [10], that has been adopted for rare
disease research and beyond [38]. Policies related to the
development of therapies have led funders to mandate
Orphan Drug Designation and Protocol Assistance by reg-
ulatory agencies for some of their programmes ear-marked
to support clinical trials in rare diseases. More recently,
IRDiRC has developed a number of new initiatives, e.g., the
“IRDiRC Recognized Resources” program and Scientific
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Committee-directed Task Forces, to further the impact of
the Policies and Guidelines. “IRDiRC Recognized Resour-
ces” highlights publicly available resources that are peer-
reviewed and have been assessed to comply with the Poli-
cies and Guidelines [11]. IRDiRC Task Forces address
particular topics or questions related to rare disease
research, identify challenges to efficiency and effectiveness
in global rare disease research, suggest and/or create solu-
tions including standards and tools, and publish recom-
mendations to further reinforce these policies and guidelines
[39]. IRDiRC Policies and Guidelines may also have an
impact on member organizations beyond their rare
disease programmes, on other initiatives and collaborations,
e.g., health system policy implementing HPO, ORPHA
nomenclature, and data sharing policies. IRDiRC is inves-
tigating additional ways to promulgate the policies and
guidelines and assess their impact, and will update them as
required.
More broadly from a genomics policy perspective,
IRDiRC partners with the Global Alliance for Genomics
and Health (GA4GH) to collaboratively develop policy and
guidelines around consent and data sharing [40], and fra-
meworks for ethical and secure data sharing [41]. Similarly,
IRDiRC is linked with the Global Genomic Medicine
Collaborative (G2MC), an initiative to capture and dis-
seminate best practices for genomic medicine in bioinfor-
matics, education, evidence, pharmacogenomics, and policy
across the global genomic medicine community. Other
partnerships and initiatives specifically targeting rare dis-
eases that are linked with IRDiRC include, but are not
limited to: RD-Connect; TREAT-NMD; CARE for
RARE Canada; Human Variome Project; RARE-Best-
practices; RD-Action; European Reference Networks
(ERNs); the USA Office of Rare Diseases Research with its
Rare Diseases Clinical Research Network (RDCRN); and
the Undiagnosed Diseases Network International (UDNI).
IRDiRC is committed to working broadly with its partners
to facilitate delivery of its goals. (See Supplementary
document 1 for description of IRDiRC’s partner initiatives).
The role of patient organizations must also be empha-
sized. Representatives from patient organizations are parti-
cipants in IRDiRC Committees and Task Forces in order to
ensure patients’ views are taken into consideration during
strategic planning and on all activities, carried out in line
with the agreed principles described in the IRDiRC Policies
and Guidelines. Patient organizations that are also funders
of research reinforce the implementation of these principles
through their funding programmes, external representatives
are systematically invited to provide their input on various
aspects including recommendations to improve rare disease
research policies and practices, and a newly formed Patient
Advocates Constituent Committee will identify further
common barriers to be addressed through collaborative
actions that apply the IRDiRC Policies and Guidelines.
Conclusions
IRDiRC is focused on accelerating progress in the field of
rare disease research through international cooperation and
collaboration, with the ultimate goals of enabling the means
to provide a diagnosis for all rare diseases patients, and to
contribute to the development of new therapies for rare
diseases. In order to increase the joint impact of rare dis-
eases investment by funding agencies, industry, researchers,
regulators, and rare diseases patient advocates, harmoniza-
tion of efforts that address common roadblocks is needed.
To assist in this task, IRDiRC developed a set of Policies
and Guidelines, which are the principles that IRDiRC
members agree to adhere to, focused on data sharing and
standards, ontologies, diagnostics, biomarkers, patient
registries, biobanks, natural history, therapeutics, models,
publication and intellectual property, and communications
about the Consortium. The IRDiRC Policies and Guidelines
are the detailed and worldwide agreements of major public
and private funding organizations to govern rare disease
research, with the Consortium representing over 2 billion
US dollar of investments. While it is too early to fully gauge
the depth and magnitude of impact on rare disease research
and patient benefit, the IRDiRC Policies and Guidelines
have already significantly contributed in improving trans-
parency and collaboration in this field. IRDiRC is now
making steps towards addressing gaps and barriers in rare
disease research; Task Forces are established to specifically
address some of these gaps through policy recommenda-
tions and/or technical solutions. Rare disease research has
made considerable progress in the last decade, and the
IRDiRC Policies and Guidelines will further push the dis-
covery progress of rare disease diagnosis and treatment,
thereby advancing this important field of research.
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